Cynosure Group LLC acquired a new position in STERIS plc (NYSE:STE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,357 shares of the medical equipment provider's stock, valued at approximately $279,000.
A number of other institutional investors have also recently bought and sold shares of STE. Geode Capital Management LLC raised its holdings in shares of STERIS by 2.4% during the fourth quarter. Geode Capital Management LLC now owns 2,359,748 shares of the medical equipment provider's stock worth $483,775,000 after acquiring an additional 56,123 shares in the last quarter. National Bank of Canada FI raised its stake in shares of STERIS by 16.3% during the 4th quarter. National Bank of Canada FI now owns 46,221 shares of the medical equipment provider's stock worth $9,501,000 after purchasing an additional 6,486 shares in the last quarter. HighPoint Advisor Group LLC purchased a new stake in shares of STERIS during the 4th quarter worth about $201,000. Franklin Resources Inc. lifted its holdings in shares of STERIS by 45.1% during the 4th quarter. Franklin Resources Inc. now owns 1,216,821 shares of the medical equipment provider's stock valued at $250,130,000 after buying an additional 378,252 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of STERIS by 4,534.6% in the 4th quarter. Wellington Management Group LLP now owns 219,032 shares of the medical equipment provider's stock valued at $45,024,000 after buying an additional 214,306 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts have issued reports on the stock. JMP Securities reiterated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a research note on Thursday, February 6th. Stephens reaffirmed an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Finally, Piper Sandler increased their target price on shares of STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Monday, February 3rd. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $258.75.
Read Our Latest Report on STE
STERIS Stock Performance
Shares of STERIS stock traded down $8.25 on Friday, reaching $213.16. The stock had a trading volume of 1,201,030 shares, compared to its average volume of 533,170. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The business's 50-day moving average price is $223.23 and its two-hundred day moving average price is $220.57. The stock has a market cap of $20.94 billion, a P/E ratio of 45.26 and a beta of 0.87. STERIS plc has a fifty-two week low of $197.82 and a fifty-two week high of $248.24.
STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, sell-side analysts forecast that STERIS plc will post 9.08 EPS for the current year.
STERIS Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Friday, March 21st. Shareholders of record on Thursday, February 20th were issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.07%. The ex-dividend date was Thursday, February 20th. STERIS's dividend payout ratio (DPR) is currently 48.41%.
STERIS Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Stories
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
